Peregrine announces patent grant for angiogenesis therapy.(Peregrine Pharmaceuticals Inc.)
Publication Date: 01-FEB-04
Publication Title: BIOTECH Patent News
Format: Online
Company: Peregrine Pharmaceuticals Inc.~Intellectual property

Read this article now
Try Goliath Business News - FREE!
You can view this article PLUS...

  • Over 5 million business articles
  • Hundreds of the most trusted magazines, newswires, and journals (see list)
  • Premium business information that is timely and relevant
  • Unlimited Access

Now for a Limited Time, try Goliath Business News
Free for 7 Days!

Tell Me More   Terms and Conditions

Purchase this article for $4.95

Description

Peregrine Pharmaceuticals (Tustin, CA) announced the issuance of United States Patent 6,524,583, entitled "Antibody Methods for Selectively Inhibiting VEGF," which covers methods for treating a variety of diseases that are dependent on the growth of new blood vessels in a process called angiogenesis. Therapeutic agents covered under the newly issued patent are based on the use of antibodies that bind to and selectively neutralize the blood vessel growth factor VEGF (Vascular Endothelial Growth Factor).

The new patent provides methods for treating cancer, arthritis, eye diseases and other conditions in which...



More articles from BIOTECH Patent News
Isotechnika obtains United States patent.(Brief Article), February 01, 2004
ZymoGenetics obtains United States patent.(Brief Article), February 01, 2004
North Carolina State University obtains United States patent.(Brief Ar..., February 01, 2004
Tokai University obtains United States patent.(Brief Article), February 01, 2004
Boston Medical Center obtains United States patent.(Boston Medical Cen..., February 01, 2004

Looking for additional articles?
Click here to search our database of over 3 million articles.